The Medicines and Healthcare products Regulatory Agency said on 4 August 2026 that two investigational medicines had been granted Innovation Passports under the UK's Innovative Licensing and Access Pathway (ILAP): a biological medicine for hepatocellular carcinoma, the most common form of liver cancer, and a small-molecule medicine for dementia with Lewy bodies. The agency did not name either product. On the same day the Boston company CervoMed said the dementia with Lewy bodies passport had been awarded to neflamapimod, its oral p38 alpha kinase inhibitor. The MHRA's notice does not describe the award as the pathway's first for dementia with Lewy bodies.

An Innovation Passport is entry to ILAP, which is run jointly by the MHRA, NHS England, the National Institute for Health and Care Excellence, the Scottish Medicines Consortium, the All Wales Therapeutics and Toxicology Centre and the Department of Health in Northern Ireland. It gives a developer earlier and more coordinated regulatory, NHS and health technology assessment input while evidence is still being generated. The MHRA said in its own notice that the products awarded passports are still in development and that any future availability will depend on the evidence of safety, effectiveness and value. James Pound, the agency's executive director for innovation and compliance, said the awards demonstrated "the breadth and ambition" of the pathway. Applications for the next ILAP round opened on 4 August 2026 and close on 4 November 2026.

The clinical record behind the drug is mixed, and the designation carries no judgement on it. CervoMed's phase 2b RewinD-LB trial randomised 159 participants with dementia with Lewy bodies to neflamapimod or placebo for 16 weeks, followed by a 32-week drug-only extension. Topline results announced on 10 December 2024 did not reach statistical significance on the primary endpoint, change in the Clinical Dementia Rating Sum of Boxes, or on any key secondary endpoint, and the company said target plasma drug concentrations had not been achieved during the double-blind phase. A conference abstract published in Alzheimer's and Dementia on 23 December 2025 by investigators including the company records the same shortfall in drug exposure in that initial phase. Later analyses reported by the company from the extension period are exploratory and open-label, with no concurrent placebo group.

There is no licensed disease-modifying treatment for dementia with Lewy bodies in the United Kingdom, the United States or the European Union. CervoMed said in November 2025 that it had written feedback from the US Food and Drug Administration on a single global, randomised, placebo-controlled phase 3 trial of about 300 patients, with 32 weeks of blinded treatment, and in its 4 August statement said it was seeking a strategic partner to take the drug into that trial. Jacqui Cannon, chief executive of the Lewy Body Society, said in the company's release that it was "encouraging for the DLB community" to see a treatment for the condition in such a programme.